Genetics of age-related macular degeneration

Michael Klein, Peter J. Francis

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Gene discoveries will lead to more effective therapies for AIMED by identifying specific underlying disease mechanisms that might be corrected by drugs or gene therapy. For example, investigations are currently being carried out using pigment epithelium-derived factor (PEDE). The gene for this potent inhibitor of angiogenesis has been incorporated into an adenoviral vector and delivered into the eye by intravitreal injection [95] to inhibit growth of new blood vessels in eyes with neovascular AMD. In the future, as the genetics of this complex disease are unraveled, more effective treatments and preventative measures that target specific molecular defects underlying the development of AMD can be expected.

Original languageEnglish (US)
Pages (from-to)567-574
Number of pages8
JournalOphthalmology Clinics of North America
Volume16
Issue number4
DOIs
StatePublished - Dec 2003

Fingerprint

Macular Degeneration
Inborn Genetic Diseases
Intravitreal Injections
Angiogenesis Inhibitors
Genetic Association Studies
Genetic Therapy
Blood Vessels
Drug Therapy
Therapeutics
Growth
Genes
pigment epithelium-derived factor

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Genetics of age-related macular degeneration. / Klein, Michael; Francis, Peter J.

In: Ophthalmology Clinics of North America, Vol. 16, No. 4, 12.2003, p. 567-574.

Research output: Contribution to journalArticle

Klein, Michael ; Francis, Peter J. / Genetics of age-related macular degeneration. In: Ophthalmology Clinics of North America. 2003 ; Vol. 16, No. 4. pp. 567-574.
@article{61e7b92e95814818b15983de7a63403b,
title = "Genetics of age-related macular degeneration",
abstract = "Gene discoveries will lead to more effective therapies for AIMED by identifying specific underlying disease mechanisms that might be corrected by drugs or gene therapy. For example, investigations are currently being carried out using pigment epithelium-derived factor (PEDE). The gene for this potent inhibitor of angiogenesis has been incorporated into an adenoviral vector and delivered into the eye by intravitreal injection [95] to inhibit growth of new blood vessels in eyes with neovascular AMD. In the future, as the genetics of this complex disease are unraveled, more effective treatments and preventative measures that target specific molecular defects underlying the development of AMD can be expected.",
author = "Michael Klein and Francis, {Peter J.}",
year = "2003",
month = "12",
doi = "10.1016/S0896-1549(03)00063-4",
language = "English (US)",
volume = "16",
pages = "567--574",
journal = "Ophthalmology Clinics of North America",
issn = "0896-1549",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Genetics of age-related macular degeneration

AU - Klein, Michael

AU - Francis, Peter J.

PY - 2003/12

Y1 - 2003/12

N2 - Gene discoveries will lead to more effective therapies for AIMED by identifying specific underlying disease mechanisms that might be corrected by drugs or gene therapy. For example, investigations are currently being carried out using pigment epithelium-derived factor (PEDE). The gene for this potent inhibitor of angiogenesis has been incorporated into an adenoviral vector and delivered into the eye by intravitreal injection [95] to inhibit growth of new blood vessels in eyes with neovascular AMD. In the future, as the genetics of this complex disease are unraveled, more effective treatments and preventative measures that target specific molecular defects underlying the development of AMD can be expected.

AB - Gene discoveries will lead to more effective therapies for AIMED by identifying specific underlying disease mechanisms that might be corrected by drugs or gene therapy. For example, investigations are currently being carried out using pigment epithelium-derived factor (PEDE). The gene for this potent inhibitor of angiogenesis has been incorporated into an adenoviral vector and delivered into the eye by intravitreal injection [95] to inhibit growth of new blood vessels in eyes with neovascular AMD. In the future, as the genetics of this complex disease are unraveled, more effective treatments and preventative measures that target specific molecular defects underlying the development of AMD can be expected.

UR - http://www.scopus.com/inward/record.url?scp=0348225261&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0348225261&partnerID=8YFLogxK

U2 - 10.1016/S0896-1549(03)00063-4

DO - 10.1016/S0896-1549(03)00063-4

M3 - Article

C2 - 14740997

AN - SCOPUS:0348225261

VL - 16

SP - 567

EP - 574

JO - Ophthalmology Clinics of North America

JF - Ophthalmology Clinics of North America

SN - 0896-1549

IS - 4

ER -